Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Panelists discuss how, PSMA PET imaging significantly enhances surgical decision-making in prostate cancer by precisely identifying tumor location, extent, and metastatic spread with superior sensitivity compared to conventional imaging. This molecular targeting enables more accurate surgical planning, improved patient selection for radical prostatectomy versus targeted approaches, and better identification of lymph node involvement, ultimately allowing for personalized treatment strategies that maximize oncological outcomes while minimizing unnecessary interventions.
Video content above is prompted by the following:
- Briefly discuss the role of PSMA PET imaging in assessing for biochemical recurrence and how imaging guides treatment decisions in this setting.
- What is your typical approach when monitoring for biochemical recurrence in this setting?
- When do you typically order PSMA PET imaging when monitoring for disease recurrence?
- How does PSMA PET imaging guide your treatment decisions in this setting?
- What do available data from pivotal trials demonstrate and how do these finding inform your decisions in this setting?
- LOCATE – Axumin (fluciclovine F18). Andriole et al. J Urol. 2019
- PSMA-BCR – Illuccix (gallium Ga68 gozetotide). Calais et al. J Nucl Med. 2018
- CONDOR – Pylarify (piflufolastat F18). Morris et al. Clin Cancer Res. 2021
- SPOTLIGHT – Posluma (flotufolastat F18). Jani et al. J Urol. 2023
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
